Human Papillomavirus genotypes in cervical intraepithelial lesions among women at two referral centers in Brazil

Roberto Borges Bezerra; Ariani Impieri Souza; Rodrigo Alves Pinto; Miguel Angelo Martins Moreira; Liz Maria de Almeida

doi:10.30574/gscbps.2021.14.3.0064

Authors

Roberto Borges Bezerra Department of Oncology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Ariani Impieri Souza Department of Research, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Rodrigo Alves Pinto Department of Oncology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Miguel Angelo Martins Moreira Associate Researcher, Instituto Nacional de Cancer (INCA), Rio de Janeiro, Brazil.
Liz Maria de Almeida Department of Epidemiology, Instituto Nacional de Cancer (INCA), Rio de Janeiro, Brazil.

DOI:

https://doi.org/10.30574/gscbps.2021.14.3.0064

Keywords:

HPV, CIN, HSIL, LSIL, Papillomaviridae, Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms

Abstract

This study aimed to describe Human Papilloma Virus (HPV) genotypes and women with cervical intraepithelial neoplasia (CIN) sociodemographic characteristics at the oncology reference centers. A secondary data of 325 records on women with CIN were analyzed from a cohort study database conducted in two public institutions in the oncological service in the Northeast of Brazil, from July 2014 to February 2016. The HPV genotype analysis was carried out on 142 through viral DNA sequence after amplifying PCR technique and compared the sequences identified in the GenBank databases. The women were predominantly 25 to 39 years old. The 325 biopsies revealed 17.6% low-grade of cervical intraepithelial lesion (CIN1) and 82.4% high-grade of cervical intraepithelial lesion (CIN2 or CIN3). Among the 142 HPV genotypes the most prevalent was HPV-16 (51.7%), followed by HPV-35 (6.9%) and HPV-45 (6.2%). HPV-18 was in only 2.1%. There was an association between HPV-16 and high-grade lesions (CIN2 or CIN3) (p=0.008). Although HPV-16 was the predominant genotype in cervical intraepithelial lesions, especially high-grade lesions (CIN2 or CIN3), HPV-35 was the second most frequent in high-grade lesions in this population. This suggests that other HPVs may be as prevalent as those commonly known in some regions.

Metrics

Metrics Loading ...

References

GLOBOCAN (IARC): Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2018.

Instituto Nacional do Câncer (INCA): [2020 estimate of cancer incidence in Brazil]. 2020.

Reis NVS, Andrade BB, Guerra MR, Teixeira MTB, Malta DC, Passos VMA, et al. The Global Burden of Disease Study Estimates of Brazil’s Cervical Cancer Burden. Ann. Glob. Health. 2020; 86(1): 56.

Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Wines R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesion: a meta-analysis update. Int J Cancer. 2007; 121(3): 621-32.

Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7): 453-9.

Dürst M, Gissmann L, Ikenberg H, Zur Hause H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983; 80(12): 3812-5.

Colpani V, Falcetta FS, Bidinotto AB, Kops NL, Falavigna M, Hammes LS, et al. Prevalence of human papillomavirus (HPV) in Brazil: A systematic review and metha-analysis. PLoS ONE. 2020; 15(2): e0229154.

Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis BMJ 2018;360:k499.

Gravitt P, Winer R. Natural History of HPV Infection Across the Lifespan: Role of Viral Latency. Viruses. 2017; 99(10): 267.

WHO classification of tumours of female reproductive organs / edited by Robert J. Kurman [et al.]. Lyon: International Agency for Research on Cancer. 2014; 307.

Hemminki K, Chen B. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev. 2006; 15(7): 1413-4.

International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8.097 women with squamous cell carcinoma and 1.374 women with adenocarcinoma from 12 epidemiological studies. Int. J. Cancer. 2007; 120(4): 885-91.

Mascarello KC, Silva NF, Piske MT, Viana KCG, Zandonade E, Amorim MH. [Sociodemographic and clinical profile of women with cervical cancer associated with initial staging]. Rev Bras de Cancerol. 2012; 58(3): 417-26.

Thuler LCS, Bergmann A, Casado L. [Profile of Cervical Cancer Patients in Brazil, 2000-2009: Secondary Baseline Study]. Rev Bras de Cancerol. 2012; 58(3): 351-7.

Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5): 271-8.

Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447): 1757-65.

Joura EA, Giuliano AR, Iversen O, Bouchard C, Mao C, Mehlsen J, et al. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med. 2015; 372: 711-23.

Ministry of Health of Brazil: [Technical report on the human papillomavirus vaccine (HPV) in primary care. General coordination of the national immunization program].

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 781-9.

Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunization in England. Vaccine. 2013; 32: 26-32.

Chiconela FV, Chidassicua JB. Women's knowledge and attitudes regarding cervical cancer screening. Rev. Eletr. Enf. 2017; 19: a23.

Khan Z, Appleton F, Turner J. Is cervical intra-epithelial neoplasia symptomatic? J Obst Gynecol. 2009; 28(3): 336-337.

Ribeiro L, Bastos R, Vieira M, Ribeiro LC, Teixeira MT, Leite IC. [Opportunistic screening versus missed opportunities: non-adherence to Pap smear testing in women attending prenatal care]. Cad Saúde Pública. 2016; 32(6): e00001415.

Landy R, Birk H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer. 2014; 110(7): 1841–6.

Wilkinson TM, Sykes PHH, Simcock B, Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. Am J Obstet Gynecol. 2015; 212: 769.e1-7.

Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PPL, Arbyn M, Bennett P, Paraskevaidis E. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database of Systematic Reviews. 2017; 11: Art. No: CD012847.

Jensen KE, Schmieldl S, Norrild B, Frederiksin K, Lfner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013; 108(1): 234-9.

Almeida LM, Martins LF, Pontes V, et al. Human papillomavirus Genotype Distribution among Cervical Cancer Patients prior to Brazilian National HPV Immunization Program. J Environ Public Health. 2017; 1645074.

Liu Z-C, Liu W-D, Liu Y-H, Ye X-H, Chen S-D. Multiple Sexual Partners as a Potential Independent Risk Factor for Cervical Cancer: a Meta-analysis of Epidemiological Studies. Asian Pac J Cancer Prev. 2015; 16(9): 3893-900.

Murthy NS, Mathew A. Risk factors for pre-cancerous lesion of the cervix. Eur J Cancer Prev. 2000; 9(1): 5-14.

Wendland EM, Villa LL, Unger ER, Domingues CM, Benzaken AS & POP-Brazil Study Group. Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP Brazil Study. Scientific Reports. 2020; 10: 4920.

Ciapponi A, Bardach A, Glujovsky D, Gibbons L, Picconi M. Type-specific HPV Prevalence in Cervical Cancer and High-Grade Lesions in America and the Caribbean: Systematic Review and Meta-Analysis. Plos one. 2011; 6(10): e25493.

Mendonça VG, Guimarães MJB, Lima-Filho JL, Mendonça CG, Martins DBG, Crovella S, et al. [Human papillomavirus cervical infection: viral genotyping and risk factors for high-grade squamous intraepithelial lesion and cervix cancer]. Rev Bras Ginec Obstet. 2010; 32(10): 476-85.

Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, et al. The Burden of Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa. Vaccine. 2013; 31(05): F32–F46.

Castellsagué X, Menéndrez C, Loscertales MP, Kornegay JR, Santos F, Goméz-Olive F. Human Papillomavirus Genotypes in rural Mozambique. Lancet. 2001; 358(9291): 1429-30.

Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico. JAMA Netw Open. 2019; 2(11): e1915781.

De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol. 2013; 130(3): 642-51.